Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.

The risk for alopecia areata is increased among patients with lower serum levels of vitamin D and zinc, but no relationship was observed with copper.

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

The global alopecia treatment market size was valued at USD 3.48 billion in 2024 and is projected to reach from USD 3.62 billion in 2025 to USD 5.20 billion by 2033, growing at a CAGR of 4.1% during ...

HCW Biologics Inc. has received clearance of its IND application from the FDA to initiate a first-in-human phase I trial to ...

MIRAMAR, Fla. - HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company with a market capitalization of approximately $12.4 million, announced today that it has received U.S.

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...

HCW Biologics Inc. (HCWB) a clinical-stage biopharmaceutical company, Monday said that the Food and Drug Administration (FDA)has ...

Please provide your email address to receive an email when new articles are posted on . Alopecia areata was classified as early-onset, severe or prolonged. Each additional atopic comorbidity ...

Superficial cryotherapy is a novel cold-based treatment that has emerged as a potential therapy for patchy alopecia areata ...